HIV/AIDS Lipoatrophy: HAART-associated facial lipoatrophy corrected by polylactic acid implants

AIDSWEEKLY Plus; Monday, June 5, 2006
Staff Medical Writers

In a recent report published in the journal Archives of Dermatology, researchers in Italy conducted a study to "assess the efficacy, safety, and tolerability of facial injections of polylactic acid for human immunodeficiency virus (HIV) 1-associated facial lipoatrophy, which commonly affects HIV-1-infected patients receiving combination antiretroviral therapy.

"A cohort of 50 consecutive HIV-1-infected outpatients with moderate to severe facial lipoatrophy who were receiving antiretroviral therapy were recruited in one institutional center and followed up for 12 months."

"Patients received the compound subcutaneously at baseline and on days 30, 45, and 60 of the study, for a total of 4 sets of injections; if necessary, 2 additional sets of injections were allowed on days 75 and 90.

"At enrollment and during follow-up, data on patients' characteristics, facial ultrasonography, and iconography were assessed. Data for 2 questionnaires, on self-perception of severity of facial lipoatrophy and on quality of life measured by the Medical Outcomes Study-HIV, were also obtained," A.M. Cattelan and colleagues at General Hospital in Padua wrote.

"Polylactic acid injections led to a significant improvement in facial lipoatrophy," reported investigators, "confirmed by the patients' facial lipoatrophy self-perception and by the ultrasonographic evaluation.

"The mean total cutaneous thickness of each cheek increased significantly between baseline and after completing the polylactic acid injection sessions (4.3 mm [range, 2.7-6.2 mm] [p<0.001] and 4.4 mm [range, 2.7-6.1 mm] [p<0.001] on the right and left cheeks, respectively) and persisted significantly until month 12 of follow-up (3.4 mm [range, 2.3-4.9 mm] [p<0.001] and 3.3 turn [range, 1.6-5.0 mm] [p<0.001] on the right and left cheeks, respectively)."

"In addition," the authors continued, "a significant (p<0.01) improvement in overall quality of life was observed between baseline and the end of the study. No patients discontinued treatment because of toxic effects, and subcutaneous micronodules at the site of injection were never observed."

Cattelan concluded, "Polylactic acid injections can be considered an effective, safe, and simple procedure in HIV-related facial lipoatrophy. The overall improvement of quality of life was clearly associated with the correction of lipoatrophy, reflecting the positive effect of this strategy on patient well-being."

Cattelan and colleagues published their study in Archives of Dermatology (Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. Arch Dermatol. 2006 Mar;142(3):329-34).

For additional information, contact A.M. Cattelan, General Hospital, Dept. Infectious Disease, Via Giustiniani 2, I-35128 Padua, Italy.

The publisher's contact information for the journal Archives of Dermatology is: American Medical Association, 515 N State St., Chicago, IL 60610-0946, USA.

Keywords: Padua, Italy, HIV/AIDS, Facial Lipoatrophy, Polylactic Acid Implant, Quality of Life, Safety & Efficacy.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Cattelan AM, Bauer U, Trevenzoli M, et al., "Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy", Arch Dermatol. 2006 Mar;142(3):329-34.

PubMED Related articles Search

2006-06-05
AW060602

Copyright © 2006 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.